CA2632200A1 - Trioxane dimers having high anticancer and long-lasting antimalarial activities - Google Patents

Trioxane dimers having high anticancer and long-lasting antimalarial activities Download PDF

Info

Publication number
CA2632200A1
CA2632200A1 CA002632200A CA2632200A CA2632200A1 CA 2632200 A1 CA2632200 A1 CA 2632200A1 CA 002632200 A CA002632200 A CA 002632200A CA 2632200 A CA2632200 A CA 2632200A CA 2632200 A1 CA2632200 A1 CA 2632200A1
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
compound
mmol
art art
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002632200A
Other languages
English (en)
French (fr)
Inventor
Gary H. Posner
Ikhyeon Paik
Kristina Borstnik
Wonsuk Chang
Sandra Sinishtaj
William Anthony Maio
John Gaetano D'angelo
Lauren Elaine Woodard
Alvin Soloman Kalinda
Aimee R. Usera
Lindsey Catherine Hess
Andrew Scott Rosenthal
Seongho Oh
Astrid C. Baege
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2632200A1 publication Critical patent/CA2632200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pest Control & Pesticides (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002632200A 2005-12-08 2006-11-17 Trioxane dimers having high anticancer and long-lasting antimalarial activities Abandoned CA2632200A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74854805P 2005-12-08 2005-12-08
US60/748,548 2005-12-08
US76512506P 2006-02-03 2006-02-03
US60/765,125 2006-02-03
US79481106P 2006-04-25 2006-04-25
US60/794,811 2006-04-25
PCT/US2006/044845 WO2007067333A2 (en) 2005-12-08 2006-11-17 Trioxane dimers having high anticancer and long-lasting antimalarial activities

Publications (1)

Publication Number Publication Date
CA2632200A1 true CA2632200A1 (en) 2007-06-14

Family

ID=38123365

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002632200A Abandoned CA2632200A1 (en) 2005-12-08 2006-11-17 Trioxane dimers having high anticancer and long-lasting antimalarial activities

Country Status (10)

Country Link
US (1) US20090291923A1 (https=)
EP (1) EP1962596A4 (https=)
JP (1) JP2009518397A (https=)
KR (1) KR20080081310A (https=)
AU (1) AU2006323040A1 (https=)
BR (1) BRPI0619759A2 (https=)
CA (1) CA2632200A1 (https=)
IL (1) IL191597A0 (https=)
MX (1) MX2008007358A (https=)
WO (1) WO2007067333A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2141499A1 (en) * 2008-07-02 2010-01-06 Apoptec AG COPD diagnosis
US8592611B2 (en) 2008-07-17 2013-11-26 The Johns Hopkins University Trioxane dimer sulfur compounds
WO2010032165A2 (en) * 2008-09-19 2010-03-25 North-West University Prodrugs of artemisinin
US8884032B2 (en) 2009-05-19 2014-11-11 The Johns Hopkins University Trioxane monomers and dimers
WO2011071947A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives
US20110144067A1 (en) * 2009-12-07 2011-06-16 Toscano John P N-Acyloxysulfonamide and N-Hydroxy-N-Acylsulfonamide Derivatives
US9493480B2 (en) 2011-04-15 2016-11-15 The Johns Hopkins University Monomeric trioxane amide sulfur compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121749A0 (en) * 1997-09-11 1998-02-22 Yeda Res & Dev 2,3-dioxabicycloÚ3.3.1¾nonane derivatives and antimalarial pharmaceutical compositions comprising them
US6160004A (en) * 1997-12-30 2000-12-12 Hauser, Inc. C-10 carbon-substituted artemisinin-like trioxane compounds having antimalarial, antiproliferative and antitumor activities
AU2003233509A1 (en) * 2002-05-07 2003-11-11 University Of Mississipi Artemisinin-based peroxide compounds as broad spectrum anti-infective agents
WO2004028476A2 (en) * 2002-09-27 2004-04-08 Johns Hopkins University Artemisinin-derived trioxane dimers

Also Published As

Publication number Publication date
IL191597A0 (en) 2009-02-11
WO2007067333A2 (en) 2007-06-14
WO2007067333A3 (en) 2008-01-31
KR20080081310A (ko) 2008-09-09
AU2006323040A1 (en) 2007-06-14
EP1962596A2 (en) 2008-09-03
JP2009518397A (ja) 2009-05-07
US20090291923A1 (en) 2009-11-26
EP1962596A4 (en) 2010-09-22
MX2008007358A (es) 2008-11-10
BRPI0619759A2 (pt) 2011-10-18

Similar Documents

Publication Publication Date Title
US11459327B1 (en) Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof
AU2018203354B2 (en) Hepatitis B antiviral agents
ES2651019T3 (es) Compuestos macrocíclicos útiles como inhibidores de cinasas y de HSP90
CA3096790A1 (en) Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates
DK2805955T3 (en) 1-OXO / ACYLATION-14-ACYLED ORIDONINE DERIVATIVE, PROCEDURE FOR PREPARING IT AND USING THEREOF
EA019749B1 (ru) Противовирусные соединения
US20250195475A1 (en) Cdk2 inhibitor and preparation method and use thereof
CA3082499A1 (en) Quinazolinone compound and application thereof
AU2020385527A1 (en) Compound used as EGFR kinase inhibitor and use thereof
JP2015504075A (ja) ７−置換ハンファンギチンｂ誘導体、その調製方法及び使用
CA2632200A1 (en) Trioxane dimers having high anticancer and long-lasting antimalarial activities
CA3099605A1 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CN116528850B (zh) 具有抗病毒活性的酰胺衍生物
Kim et al. Prodrugs of 4′-demethyl-4-deoxypodophyllotoxin: synthesis and evaluation of the antitumor activity
EP2358198A1 (en) Hydroxyethylamino sulfonamide derivatives
EP2746286A1 (en) Aminated derivative of homoharringtonine, preparation method therefor, and application thereof
CN101325874A (zh) 具有高抗癌活性和长效抗疟活性的三噁烷二聚物
US20060247246A1 (en) 9-Amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives
CN118056834A (zh) 稠环吡啶酮衍生物及其制备方法和用途
EP2474550A1 (en) Derivatives of Englerin for the treatment of cancer
CA2993378C (en) Vinblastine 20' amides: synthetic analogs that maintain or improve potency and simultaneously overcome pgp-derived efflux and resistance
EP3310360B1 (en) Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
DK2765133T3 (en) An acylated derivative of homoharringtonine, process for the preparation thereof and use thereof
KR101071359B1 (ko) 항암 활성을 가지는 2-메틸-2-알킬-6-아미도-2ｈ-벤조피란 유도체
JP5994059B2 (ja) 抗マラリア活性を有するアザアルテミシニン誘導体及びその製造方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131119